CDK4/6 inhibitor: from quiescence to senescence
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The CDK4 and CDK6 kinases (CDK4/6) are the first cyclin dependent kinases to be activated and initiate transition through G1 phase of the cell cycle. In response to mitogenic growth factors, the CDK4/6 kinase together with one of three D-type cyclins (D1, D2, D3) initiates G1 progression by virtue of its capacity to phosphorylate the retinoblastoma protein (RB), a bona fide tumor suppressor and Gate Keeper of cell division. Phosphorylation of RB in turn results in de-repression of E2F transcription factors thereby triggering expression of genes whose products drive S-phase entry and progression (1). Cyclin D1 dysregulation occurs in a majority of human cancers, a direct result of gene amplification or mutations that disrupt its protein degradation. CDK4 amplification or activating point mutations are also observed in select malignancies. The end result of such aberrations is elevated CDK4 catalytic function, increased cell division and decreased dependence on extracellular mitogenic growth factors for cell proliferation. These observations have contributed to significant efforts to develop selective small molecule CDK4/6 inhibitors with the hope that such entities would have significant anti-cancer benefit. PD0332991 (Palbociclib), a highly selective inhibitor of CDK4 (IC50: 0.011 μM) and CDK6 (IC50: 0.016 μM), has been shown to be highly efficacious in a variety of cell culture models with regard to its capacity to suppress cell cycle progression through inhibition of CDK4/6 kinase activity in an RB-dependent manner and it is currently being tested in clinical trials for malignancies such as mantle cell lymphoma, breast cancer, and colorectal cancer (2). While acute inhibition of CDK4/6 is associated with reversible cell cycle withdraw or quiescence, some recent investigations have provided provocative evidence that Palbociclib treatment can in fact trigger irreversible withdraw, a state referred to as senescence (3, 4, 5). However the mechanisms that determine whether Palbociclib evokes quiescence versus senescence are yet to be established. In work described by Kovatcheva et al a new molecular mechanism wherein MDM2 and ATRX determine cell fate following CDK4/6 inhibition in cancer cells derived from several distinct cancer etiologies such as well-differentiated and dedifferentiated liposarcoma (WD/DDLS), lung cancer, and glioma (6). In this work, WD/DDLS cell lines were classified based upon cell fate following Palbociclib exposure: quiescence (non-responders) versus senescence (responders). While both groups had the expected reduction in RB phosphorylation, the responders also exhibited a significant decrease in MDM2 levels after prolonged CDK4 inhibition. Importantly, the phenotype is RB dependent, but is p53 and p16INK4a-independent. The capacity of MDM2 knock down to trigger senescence from quiescent phase in a combination with Palbociclib in non-responders, provides evidence that the reduction of MDM2 is in fact causative in the response and no simply an indirect consequence. While the authors were unable to ascribe novel mechanistic insights with regard to MDM2 targets in the senescence response, additional experiments revealed that auto-ubiquitylation of MDM2 is essential for down regulation following Palbociclib exposure. Since MDM2 auto-ubiquitylation is regulated by HAUSP/USP7, a de-ubiquitylating enzyme, one might expect that its alteration of HAUSP/USP7 function might also impact senescence. Consistently, cell senescence could be induced by HAUSP/USP7 knockdown. However alteration of HAUSP/USP7 levels and association with MDM2 did not correlate with responder versus non-responder status demonstrating that HAUSP/USP7 does not contribute directly to determine cell fate following Palbociclib exposure. Novel molecular insights into the cell fate switch arose from interrogation of a molecule that has been implicated in tumor cell escape from senescence; ATRX, ALT (Alternative lengthening of telomeres) associated protein. Critical analysis of ATRX in responders versus non-responders revealed differential post-translational modification of the c-terminus ATRX. The nature of this modification is currently unknown, nevertheless phosphorylation is a likely candidate modification. Knockdown of ATRX in responders rescued MDM2 loss and rendered these cells refractory to senescence but not quiescence revealing a functional link among ATRX, MDM2 and cell fate. While the mechanistic insights provided in this work will provide a critical foundation for further investigations of the molecular mechanisms that underlie a cells decision to undergo the conversion of quiescence to senescence (geroconversion), their impact would be limited if these same observations were not of value in clinical responses. Importantly, Kovatcheva et al also evaluated their model in biopsies available in a clinical trial utilizing Palbociclib in WD/DDLS patients revealing that MDM2 loss following Palbociclib exposure cor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Cited by
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
“Even if the mechanisms responsible for the induction of the senescence response over quiescence are not fully clarified yet (314, 359), these compounds are currently under clinical evaluation.”
BackgroundCellular senescence: Immunosurveillance and future immunotherapy
Burton, D. G. A., & Stolzing, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.001 · Cited by 221
“However, it should be noted that whilst such cells underwent cell cycle arrest, it does not mean that such cells are senescent and instead may have undergone a state of quiescence (Yoshida and Diehl, 2015).”
BackgroundThe cell fate: senescence or quiescence
Terzi, M. Y., Izmirli, M., & Gogebakan, B. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4065-0 · Cited by 208
Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells
Kim, J., Brunetti, B., Kumar, A., Mangla, A., Honda, K., & Yoshida, A. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07284-3 · Cited by 16
Self-citation
Metadata
- Authors
- Yoshida, A., & Diehl, J. A.
- Venue
- Oncoscience
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-20
- Volume
- 2
- Issue
- 11
- Pages
- 896-897
- ISSN
- 2331-4737 (ISSN-L)
- OpenAlex
- W2417576734
- Cited by
- 18
- References
- 4
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.